Intensity-modulated radiotherapy prevents lasting damage to salivary glands but not oral mucositis.

Author:

Agurto Maria Gonzalez1,Carpenter Guy2,Bozorgi Sophie2,Koller Garrit2,Fenlon Michael2,Warburton Fiona2,Bruce Kenneth2,Burke Mary3,Banerjee Avijit2

Affiliation:

1. Universidad de Los Andes, Chile

2. King's College London

3. Guy's and St Thomas' NHS Foundation Trust

Abstract

Abstract Objective: This study aimed to assess the salivary protein composition variations in head and neck cancer patients (HNC) undergoing Intensity-Modulated Radiotherapy (IMRT) and examined the correlation with the clinical onset/severity of oral mucositis (OM). Methods Saliva samples/clinical data were obtained from 40 HNC patients pre-IMRT(T0) and post-IMRT (T1=6m, T2=12m) treated at Guy’s Hospital (ethics approval/consent). Salivary flow rate (SFR), protein concentration (TPC) and secretion rate (TPSR) were determined from unstimulated, whole-mouth saliva samples and compared to pre-treatment levels. Clinical parameters/side effects such as OM was assessed, salivary proteins were quantified using BCA assay, SDS-PAGE/PAS-staining determined MUC5B and MUC7, ELISA assays: IgA, cystatin S and albumin; α-amylase activity by kinetic assays. Results 95 % patients experienced OM during IMRTwith 33 reaching grade 2&3. Furthermore, 6 months post-IMRT, a significant reduction, in SFR, TPSR, α-amylase and cystatin S compared with baseline. Remarkably IMRT did not significantly alter MUC5B/MUC7, and IgA secretion rates at any timepoint. Moreover, there were significant/negative correlations between IgA concentration at T0 with OM onset/severity during the cancer treatment, (p = 0.006). Conclusion This study reveals that IMRT prevents damage to salivary glands but does not prevent OM, suggesting that salivary mucins may not be involved in the onset /severity of OM.

Publisher

Research Square Platform LLC

Reference43 articles.

1. Barsouk, medical sciences Review Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma;Murray-Stewart T,2023

2. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers/incidence. 2023, (n.d.).

3. Biomarkers in saliva for the detection of oral squamous cell carcinoma and their potential use for early diagnosis: a systematic review;Gualtero DF;Acta Odontol Scand,2016

4. Mucositis: Pathobiology and management;Villa A;Curr Opin Oncol,2015

5. Pharmacotherapy for the management of cancer regimen-related oral mucositis;Villa A;Expert Opin Pharmacother,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3